Oncolytics Biotech Stock Buy Hold or Sell Recommendation
| ONC Stock | CAD 1.26 0.01 0.79% |
Assuming the 90 days trading horizon and your highly speculative risk level, our recommendation regarding Oncolytics Biotech is 'Strong Sell'. The recommendation algorithm takes into account all of Oncolytics Biotech's available fundamental, technical, and predictive indicators you will find on this site.
Check out Oncolytics Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide. In addition, we conduct extensive research on individual companies such as Oncolytics and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Oncolytics |
Execute Oncolytics Biotech Buy or Sell Advice
The Oncolytics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Oncolytics Biotech. Macroaxis does not own or have any residual interests in Oncolytics Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oncolytics Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Oncolytics Biotech Trading Alerts and Improvement Suggestions
| Oncolytics Biotech had very high historical volatility over the last 90 days | |
| Oncolytics Biotech may become a speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. | |
| Latest headline from news.google.com: Stocks In Play Oncolytics Biotech Inc - Barchart |
Oncolytics Biotech Returns Distribution Density
The distribution of Oncolytics Biotech's historical returns is an attempt to chart the uncertainty of Oncolytics Biotech's future price movements. The chart of the probability distribution of Oncolytics Biotech daily returns describes the distribution of returns around its average expected value. We use Oncolytics Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oncolytics Biotech returns is essential to provide solid investment advice for Oncolytics Biotech.
| Mean Return | 0.10 | Value At Risk | -5.16 | Potential Upside | 6.47 | Standard Deviation | 5.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oncolytics Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oncolytics Biotech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 448.1K | 17.1M | 10.0M | (29.6M) | 23.2M | 24.4M | |
| Free Cash Flow | (19.9M) | (22.1M) | (22.7M) | (23.4M) | (28.5M) | (27.0M) | |
| Depreciation | 485.6K | 446.2K | 452.1K | 392K | 403K | 300.3K | |
| Capital Expenditures | 10.9K | 29.3K | 285.9K | 55K | 8K | 7.6K | |
| Net Income | (33.1M) | (22.5M) | (26.3M) | (24.8M) | (27.8M) | (29.1M) | |
| End Period Cash Flow | 14.1M | 31.2M | 41.3M | 11.7M | 34.9M | 19.4M | |
| Other Non Cash Items | 94.8K | 68.5K | 91.7K | (1.7M) | (4.9M) | (4.7M) | |
| Investments | (10.9K) | (29.3K) | (285.9K) | (20.4M) | 20.2M | 21.2M | |
| Change To Netincome | 14.5M | (219.4K) | 4.3M | 697K | 801.6K | 761.5K |
Oncolytics Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oncolytics Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oncolytics Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oncolytics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.19 | |
β | Beta against Dow Jones | -0.96 | |
σ | Overall volatility | 5.26 | |
Ir | Information ratio | -0.002 |
Oncolytics Biotech Volatility Alert
Oncolytics Biotech shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oncolytics Biotech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oncolytics Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Oncolytics Biotech Fundamentals Vs Peers
Comparing Oncolytics Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oncolytics Biotech's direct or indirect competition across all of the common fundamentals between Oncolytics Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oncolytics Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oncolytics Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oncolytics Biotech to competition |
| Fundamentals | Oncolytics Biotech | Peer Average |
| Return On Equity | -1.38 | -0.31 |
| Return On Asset | -0.71 | -0.14 |
| Current Valuation | 79.35 M | 16.62 B |
| Shares Outstanding | 77.07 M | 571.82 M |
| Shares Owned By Insiders | 3.81 % | 10.09 % |
| Shares Owned By Institutions | 1.76 % | 39.21 % |
| Number Of Shares Shorted | 439.37 K | 4.71 M |
| Price To Earning | (4.18) X | 28.72 X |
| Price To Book | 10.81 X | 9.51 X |
| EBITDA | (33.71 M) | 3.9 B |
| Net Income | (27.75 M) | 570.98 M |
| Cash And Equivalents | 11.67 M | 2.7 B |
| Cash Per Share | 0.72 X | 5.01 X |
| Total Debt | 423 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 8.81 X | 2.16 X |
| Book Value Per Share | 0.37 X | 1.93 K |
| Cash Flow From Operations | (28.45 M) | 971.22 M |
| Short Ratio | 2.20 X | 4.00 X |
| Earnings Per Share | (0.36) X | 3.12 X |
| Target Price | 6.75 | |
| Beta | 1.51 | -0.15 |
| Market Capitalization | 97.11 M | 19.03 B |
| Total Asset | 38.82 M | 29.47 B |
| Retained Earnings | (446 M) | 9.33 B |
| Working Capital | 33.94 M | 1.48 B |
| Current Asset | 26.92 M | 9.34 B |
| Current Liabilities | 2.71 M | 7.9 B |
| Net Asset | 38.82 M |
Oncolytics Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oncolytics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Oncolytics Biotech Buy or Sell Advice
When is the right time to buy or sell Oncolytics Biotech? Buying financial instruments such as Oncolytics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small & Mid Caps ETFs Thematic Idea Now
Small & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Oncolytics Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.